← 產業報告目錄

Women’s Health Market Research Report by Product (Contraceptive, Fertility and Ovulation Induction Drugs, Vaginal and Uterine Products, Bone Health Agents, Pain and Symptom Management, Others), by Therapeutic Area (Reproductive Health and Fertility, Menopause and Hormonal Disorders, Gynaecological Disorders and Others), by Age Group (Below 30, 31-40, 41-50, and Above 51), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Supermarket and Hypermarket, Online Channels and others), by Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-05-02頁數 252報告編號 MRFRHC2248CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

The global women’s health market was valued at USD 58,444.46 million in 2025 and is projected to reach USD 114,925.76 million by 2035. The market is expected to grow at a CAGR of 6.93% during the forecast period, driven by rising awareness of women-specific healthcare needs and increasing investments in advanced treatment solutions. Rising Diagnosis and Early Detection of Gynaecological Disorders Being diagnosed is just the beginning of treatment and management for women suffering from gynaecological issues such as endometriosis, fibroids, ovarian cysts, and cervical cancer, which are among the greatest inducers of the worldwide female health market. Partly, this increased demand has been due to awareness programs and other advanced means of diagnostics coupled with additional screening, which have given rise to the earlier detection and timely treatment of these conditions. Segment-Wise Market Insights By Product • Contraceptive – Rising demand for family planning solutions. • Fertility and Ovulation Induction Drugs – Increasing infertility cases driving treatment adoption. • Vaginal and Uterine Products – Growing focus on gynecologically care products. • Bone Health Agents – Higher osteoporosis prevalence supporting market growth. • Pain and Symptom Management – Expanding use for menstrual pain relief. • Others – Emerging therapies widening women’s healthcare applications. By Therapeutic Area • Reproductive Health and Fertility – Increasing reproductive health awareness among women. • Menopause and Hormonal Disorders – Rising menopause management treatment demand globally. • Gynaecological Disorders – Early diagnosis improving gynaecological treatment adoption rates. • Others – Diverse healthcare applications supporting segment expansion. By Age Group • Below 30 – High contraceptive and reproductive healthcare demand. • 31–40 – Fertility treatments witnessing increased adoption globally. • 41–50 – Hormonal imbalance treatments gaining significant traction. • Above 51 – Growing demand for menopause care therapies. By Distribution Channel • Retail Pharmacy – Easy accessibility boosting women’s health product sales. • Hospital Pharmacy – Increasing hospital-based treatment and medication dispensing. • Supermarket and Hypermarket – Convenient product availability supporting consumer purchases. • Online Channels – E-commerce platforms driving digital healthcare accessibility. • Others – Alternative distribution networks expanding product reach. The global women's health market is dominated by the North American region due to the availability of modern healthcare facilities, larger healthcare expenditure, and digital health technologies. European countries, on the other hand, are benefiting from preventive healthcare programs and aged populations. Asia Pacific, however, is gaining ground as the most rapidly growing area as consumers become more healthcare aware, leading to better and more frequent usage of reproductive and maternal healthcare services. Strategic Expansion in Molecular Imaging On January 2026, Bayer AG expanded its precision cardiology portfolio by acquiring the investigational molecular imaging agents, AT-01 and AT-05, from Attralus. This acquisition helps Bayer increase its stake in the rapidly evolving molecular imaging market and at the same time, it is the first step in providing innovative diagnostic solutions for cardiac amyloidosis detection. Expanding Demand for Safer Women’s Health Solutions Transitioning away from hormone-based contraceptives and menopause therapies is a robust strategic opportunity in the global women's health market. Increasing education on the side effects of hormonal treatments has resulted in the desire for the adoption of non-hormonal contraceptives and more personalized and safer healthcare options. Key Report Attributes • Market Size 2025: USD 58,444.46 Million • Market Size 2035: USD 114,925.76 Million • CAGR (2025-2035): 6.93% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Product: Contraceptive - 6.77%, Fertility and Ovulation Induction Drugs - 8.24%. • By Therapeutic Area: Reproductive Health and Fertility - 6.36%, Menopause and Hormonal Disorders - 7.87%. • By Age Group: Below 30 - 6.62%, 31-40 - 7.86%. • By Distribution Channel: Retail Pharmacy - 6.45%, Hospital Pharmacy - 5.91%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ........................................... 23 1.1 OVERVIEW .......................... 23 1.2 MARKET ATTRACTIVENESS ANALYSIS ......................... 24 1.3 GLOBAL WOMEN’S HEALTH MARKET, BY PRODUCT ...... 25 1.4 GLOBAL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA ................................. 26 1.5 GLOBAL WOMEN’S HEALTH MARKET, BY AGE GROUP .............................................. 27 1.6 GLOBAL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL .......................... 28 1.7 GLOBAL WOMEN’S HEALTH MARKET, BY REGION ......... 29 2 MARKET INTRODUCTION ....................................... 31 2.1 DEFINITION ...................... 31 2.2 SCOPE OF THE STUDY ...... 31 2.3 RESEARCH OBJECTIVE ........... 31 2.4 MARKET STRUCTURE ........ 32 3 RESEARCH METHODOLOGY ................................. 33 3.1 OVERVIEW .......................... 33 3.2 DATA FLOW ........................ 35 3.2.1 DATA MINING PROCESS ...................................... 35 3.3 PURCHASED DATABASE: ........ 36 3.4 SECONDARY SOURCES: .......... 37 3.4.1 SECONDARY RESEARCH DATA FLOW: .................. 38 3.5 PRIMARY RESEARCH: ............ 39 3.5.1 PRIMARY RESEARCH DATA FLOW: ...................... 40 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................... 41 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................ 42 3.6.1 REVENUE ANALYSIS APPROACH .......................... 42 3.7 DATA FORECASTING ............... 42 3.7.1 DATA FORECASTING TYPE ................................... 43 3.8 DATA MODELING .................. 44 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ................. 44 3.8.2 DATA MODELING: ..... 45 3.9 TEAMS AND ANALYST CONTRIBUTION ................................... 47 4 MARKET DYNAMICS ............................................... 49 4.1 INTRODUCTION ................ 49 4.2 DRIVERS ............................. 50 4.2.1 RISING CONTRACEPTIVE USE .............................. 50 4.2.2 INCREASING INFERTILITY .................................... 50 4.2.3 AGING FEMALE POPULATION .............................. 51 4.2.4 RISING GYNECOLOGICAL DISORDERS ................... 51 4.3 RESTRAINTS ........................ 52 4.3.1 HORMONAL THERAPY SIDE EFFECTS ................... 52 4.3.2 CULTURAL STIGMA AND SOCIAL BARRIERS .......... 53 4.3.3 LIMITED HEALTHCARE ACCESS ........................... 53 4.4 OPPORTUNITIES ................... 54 4.4.1 RAPID EXPANSION OF FEMTECH AND DIGITAL HEALTH .................................. 54 4.4.2 DEVELOPMENT OF NON-HORMONAL THERAPIES ............................................ 55 5 MARKET FACTOR ANALYSIS ................................. 56 5.1 REGULATORY ENVIRONMENT & COMPLIANCE .......................... 56 5.2 TECHNOLOGICAL TRENDS & INNOVATION ............................... 57 5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ..................... 58 5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ................ 59 5.4.1 PRICING ANALYSIS .............................................. 59 5.4.1.1 NORTH AMERICA ..... 59 5.4.1.2 EUROPE ................. 59 5.4.1.3 ASIA PACIFIC ......... 59 5.4.1.4 LATIN AMERICA ...... 60 5.4.1.5 MIDDLE EAST & AFRICA ....................................... 60 5.4.2 REIMBURSEMENT DYNAMICS .............................. 60 5.5 MARKET ENTRY & EXIT BARRIERS .......................................... 62 5.5.1 BARRIERS TO ENTRY ........................................... 62 5.5.2 BARRIERS TO EXIT ............................................... 62 5.6 PARTNERSHIPS & COLLABORATIONS ...................................... 63 5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ............... 65 5.7.1 CONSUMER PREFERENCES .................................. 65 5.7.2 HEALTHCARE PROVIDER PREFERENCES ............... 65 5.8 PESTLE ANALYSIS ............ 65 5.8.1 POLITICAL FACTORS ........................................... 65 5.8.2 ECONOMIC FACTORS .......................................... 65 5.8.3 SOCIAL FACTORS ..... 66 5.8.4 TECHNOLOGICAL FACTORS ................................. 66 5.8.5 LEGAL FACTORS ...... 66 5.8.6 ENVIRONMENTAL FACTORS ................................ 66 5.9 PORTER'S FIVE FORCES MODEL ........................................... 67 5.9.1 THREAT OF NEW ENTRANTS ................................ 68 5.9.2 BARGAINING POWER OF SUPPLIERS .................... 68 5.9.3 BARGAINING POWER OF BUYERS ......................... 68 5.9.4 THREAT OF SUBSTITUTES ................................... 68 5.9.5 INTENSITY OF RIVALRY ....................................... 68 5.10 PRODUCT PIPELINE ANALYSIS ............................................. 69 5.11 CASE STUDY ANALYSIS ......... 70 5.12 INVESTMENT & FUNDING SCENARIOS ................................... 71 5.13 POST-MARKET SURVEILLANCE & SAFETY DATA ........................ 72 5.14 DISEASE OVERVIEW .............. 73 5.15 DIAGNOSIS ......................... 74 5.16 CURRENT TREATMENT ..... 75 6 GLOBAL WOMEN’S HEALTH MARKET, BY PRODUCT ................................... 78 6.1 OVERVIEW .......................... 78 7 GLOBAL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA ................. 82 7.1 OVERVIEW .......................... 82 8 GLOBAL WOMEN’S HEALTH MARKET, BY AGE GROUP ............................... 84 8.1 OVERVIEW .......................... 84 9 GLOBAL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL.......... 86 9.1 OVERVIEW .......................... 86 10 GLOBAL WOMEN’S HEALTH MARKET, BY REGION ....................................... 89 10.1 OVERVIEW .......................... 89 10.2 NORTH AMERICA .................. 91 10.2.1 US ........................... 97 10.2.2 CANADA .................. 101 10.3 EUROPE ............................. 105 10.3.1 GERMANY ................ 111 10.3.2 UK ........................... 115 10.3.3 FRANCE ................... 119 10.3.4 NETHERLANDS ......... 123 10.3.5 ITALY ....................... 127 10.3.6 SPAIN ...................... 131 10.3.7 REST OF EUROPE ...... 135 10.4 ASIA-PACIFIC ................... 139 10.4.1 CHINA ...................... 145 10.4.2 INDIA ....................... 149 10.4.3 JAPAN ..................... 153 10.4.4 SOUTH KOREA .......... 156 10.4.5 MALAYSIA ............... 159 10.4.6 THAILAND ................ 162 10.4.7 INDONESIA .............. 165 10.4.8 REST OF APAC ......... 168 10.5 LATIN AMERICA ................... 172 10.5.1 BRAZIL ..................... 177 10.5.2 MEXICO ................... 180 10.5.3 ARGENTINA ............. 183 10.5.4 REST OF LATIN AMERICA ..................................... 186 10.6 MIDDLE EAST & AFRICA .......... 189 10.6.1 GCC COUNTRIES ...... 194 10.6.2 SOUTH AFRICA ......... 197 10.6.3 REST OF MEA ........... 200 11 COMPETITIVE LANDSCAPE ................................... 205 11.1 INTRODUCTION ..................... 205 11.2 MARKET SHARE ANALYSIS, 2025 ......................................... 206 11.3 COMPETITOR DASHBOARD ....... 207 11.4 KEY DEVELOPMENTS ............ 208 12 COMPANY PROFILES ............................................. 210 12.1 BAYER AG .......................... 210 12.1.1 COMPANY OVERVIEW .......................................... 210 12.1.2 FINANCIAL OVERVIEW ......................................... 211 12.1.3 PRODUCTS OFFERED ........................................... 212 12.1.4 SWOT ANALYSIS ...... 212 12.1.5 KEY STRATEGIES ...... 213 12.2 MERCK KGAA ..................... 214 12.2.1 COMPANY OVERVIEW ......................................... 214 12.2.2 FINANCIAL OVERVIEW ......................................... 215 12.2.3 PRODUCTS OFFERED ........................................... 216 12.2.4 SWOT ANALYSIS ...... 216 12.2.5 KEY STRATEGIES ...... 217 12.3 PFIZER ............................... 218 12.3.1 COMPANY OVERVIEW .......................................... 218 12.3.2 PRODUCTS OFFERED ........................................... 219 12.3.3 SWOT ANALYSIS ...... 220 12.3.4 FINANCIAL ANALYSIS .......................................... 221 12.3.5 KEY STRATEGY ......... 221 12.4 RECKITT BENCKISER .............. 223 12.4.1 COMPANY OVERVIEW .......................................... 223 12.4.2 PRODUCTS OFFERED ........................................... 224 12.4.3 SWOT ANALYSIS ...... 224 12.4.4 FINANCIAL ANALYSIS .......................................... 225 12.4.5 KEY STRATEGY ......... 225 12.5 CHURCH & DWIGHT CO., INC. ............................................. 227 12.5.1 COMPANY OVERVIEW .......................................... 227 12.5.2 PRODUCTS OFFERED ........................................... 228 12.5.3 SWOT ANALYSIS ...... 229 12.5.4 FINANCIAL ANALYSIS .......................................... 230 12.5.5 KEY STRATEGY ......... 231 12.6 ABBVIE INC........................ 232 12.6.1 COMPANY OVERVIEW .......................................... 232 12.6.2 PRODUCTS OFFERED ........................................... 233 12.6.3 SWOT ANALYSIS ...... 233 12.6.4 FINANCIAL ANALYSIS .......................................... 234 12.6.5 KEY STRATEGY ......... 234 12.7 ORGANON & CO. .................. 236 12.7.1 COMPANY OVERVIEW .......................................... 236 12.7.2 PRODUCTS OFFERED ........................................... 237 12.7.3 SWOT ANALYSIS ...... 237 12.7.4 FINANCIAL ANALYSIS .......................................... 238 12.7.5 KEY STRATEGY ......... 239 12.8 MERCK & CO ...................... 240 12.8.1 COMPANY OVERVIEW .......................................... 240 12.8.2 PRODUCTS OFFERED ........................................... 241 12.8.3 SWOT ANALYSIS ...... 241 12.8.4 FINANCIAL ANALYSIS .......................................... 242 12.8.5 KEY STRATEGY ......... 242 12.9 FERRING PHARMACEUTICALS .............................................. 243 12.9.1 COMPANY OVERVIEW .......................................... 243 12.9.2 PRODUCTS OFFERED ........................................... 244 12.9.3 SWOT ANALYSIS ...... 244 12.9.4 FINANCIAL ANALYSIS .......................................... 245 12.9.5 KEY STRATEGY ......... 246 12.10 AMGEN ............................. 247 12.10.1 COMPANY OVERVIEW .......................................... 247 12.10.2 PRODUCTS OFFERED ........................................... 248 12.10.3 SWOT ANALYSIS ...... 248 12.10.4 FINANCIAL ANALYSIS .......................................... 249 13 DATA CITATIONS .......... 250
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 46 TABLE 2 PRODUCT PIPELINE 69 TABLE 3 GLOBAL WOMEN’S HEALTH MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 79 TABLE 4 GLOBAL WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 80 TABLE 5 GLOBAL WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 80 TABLE 6 GLOBAL WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 80 TABLE 7 GLOBAL WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 81 TABLE 8 GLOBAL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 83 TABLE 9 GLOBAL WOMEN’S HEALTH MARKET, BY AGE GROUP, 2019-2035 (USD MILLION) 85 TABLE 10 GLOBAL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 87 TABLE 11 GLOBAL WOMEN’S HEALTH MARKET, BY REGION, 2019-2035 (USD MILLION) 90 TABLE 12 NORTH AMERICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 92 TABLE 13 NORTH AMERICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 93 TABLE 14 NORTH AMERICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 93 TABLE 15 NORTH AMERICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 94 TABLE 16 NORTH AMERICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 94 TABLE 17 NORTH AMERICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 94 TABLE 18 NORTH AMERICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 95 TABLE 19 NORTH AMERICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 95 TABLE 20 NORTH AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 96 TABLE 21 US WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 97 TABLE 22 US WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 97 TABLE 23 US WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 98 TABLE 24 US WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 98 TABLE 25 US WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 98 TABLE 26 US WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 99 TABLE 27 US WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 99 TABLE 28 US WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 100 TABLE 29 CANADA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 101 TABLE 30 CANADA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 101 TABLE 31 CANADA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 102 TABLE 32 CANADA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 102 TABLE 33 CANADA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 102 TABLE 34 CANADA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 103 TABLE 35 CANADA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 103 TABLE 36 CANADA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 104 TABLE 37 EUROPE WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 106 TABLE 38 EUROPE WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 107 TABLE 39 EUROPE WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 107 TABLE 40 EUROPE WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 108 TABLE 41 EUROPE WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 108 TABLE 42 EUROPE WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 108 TABLE 43 EUROPE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 109 TABLE 44 EUROPE WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 109 TABLE 45 EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 110 TABLE 46 GERMANY WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 111 TABLE 47 GERMANY WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 111 TABLE 48 GERMANY WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 112 TABLE 49 GERMANY WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 112 TABLE 50 GERMANY WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 112 TABLE 51 GERMANY WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 113 TABLE 52 GERMANY WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 113 TABLE 53 GERMANY WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 114 TABLE 54 UK WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 115 TABLE 55 UK WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 115 TABLE 56 UK WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 116 TABLE 57 UK WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 116 TABLE 58 UK WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 116 TABLE 59 UK WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 117 TABLE 60 UK WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 117 TABLE 61 UK WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 118 TABLE 62 FRANCE WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 119 TABLE 63 FRANCE WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 119 TABLE 64 FRANCE WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 120 TABLE 65 FRANCE WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 120 TABLE 66 FRANCE WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 120 TABLE 67 FRANCE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 121 TABLE 68 FRANCE WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 121 TABLE 69 FRANCE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 122 TABLE 70 NETHERLANDS WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 123 TABLE 71 NETHERLANDS WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 123 TABLE 72 NETHERLANDS WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 124 TABLE 73 NETHERLANDS WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 124 TABLE 74 NETHERLANDS WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 124 TABLE 75 NETHERLANDS WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 125 TABLE 76 NETHERLANDS WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 125 TABLE 77 NETHERLANDS WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 126 TABLE 78 ITALY WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 127 TABLE 79 ITALY WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 127 TABLE 80 ITALY WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 128 TABLE 81 ITALY WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 128 TABLE 82 ITALY WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 128 TABLE 83 ITALY WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 129 TABLE 84 ITALY WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 129 TABLE 85 ITALY WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 130 TABLE 86 SPAIN WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 131 TABLE 87 SPAIN WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 131 TABLE 88 SPAIN WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 132 TABLE 89 SPAIN WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 132 TABLE 90 SPAIN WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 132 TABLE 91 SPAIN WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 133 TABLE 92 SPAIN WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 133 TABLE 93 SPAIN WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 134 TABLE 94 REST OF EUROPE WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 135 TABLE 95 REST OF EUROPE WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 135 TABLE 96 REST OF EUROPE WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 136 TABLE 97 REST OF EUROPE WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 136 TABLE 98 REST OF EUROPE WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 136 TABLE 99 REST OF EUROPE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 137 TABLE 100 REST OF EUROPE WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 137 TABLE 101 REST OF EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 138 TABLE 102 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 140 TABLE 103 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 141 TABLE 104 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 142 TABLE 105 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 142 TABLE 106 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 142 TABLE 107 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 143 TABLE 108 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 143 TABLE 109 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 143 TABLE 110 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 144 TABLE 111 CHINA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 145 TABLE 112 CHINA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 145 TABLE 113 CHINA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 146 TABLE 114 CHINA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 146 TABLE 115 CHINA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 146 TABLE 116 CHINA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 147 TABLE 117 CHINA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 147 TABLE 118 CHINA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 148 TABLE 119 INDIA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 149 TABLE 120 INDIA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 149 TABLE 121 INDIA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 150 TABLE 122 INDIA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 150 TABLE 123 INDIA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 150 TABLE 124 INDIA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 151 TABLE 125 INDIA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 151 TABLE 126 INDIA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 152 TABLE 127 JAPAN WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 153 TABLE 128 JAPAN WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 153 TABLE 129 JAPAN WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 153 TABLE 130 JAPAN WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 154 TABLE 131 JAPAN WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 154 TABLE 132 JAPAN WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 154 TABLE 133 JAPAN WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 155 TABLE 134 JAPAN WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 155 TABLE 135 SOUTH KOREA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 156 TABLE 136 SOUTH KOREA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 156 TABLE 137 SOUTH KOREA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 156 TABLE 138 SOUTH KOREA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 157 TABLE 139 SOUTH KOREA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 157 TABLE 140 SOUTH KOREA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 157 TABLE 141 SOUTH KOREA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 158 TABLE 142 SOUTH KOREA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 158 TABLE 143 MALAYSIA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 159 TABLE 144 MALAYSIA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 159 TABLE 145 MALAYSIA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 159 TABLE 146 MALAYSIA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 160 TABLE 147 MALAYSIA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 160 TABLE 148 MALAYSIA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 160 TABLE 149 MALAYSIA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 161 TABLE 150 MALAYSIA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 161 TABLE 151 THAILAND WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 162 TABLE 152 THAILAND WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 162 TABLE 153 THAILAND WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 162 TABLE 154 THAILAND WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 163 TABLE 155 THAILAND WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 163 TABLE 156 THAILAND WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 163 TABLE 157 THAILAND WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 164 TABLE 158 THAILAND WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 164 TABLE 159 INDONESIA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 165 TABLE 160 INDONESIA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 165 TABLE 161 INDONESIA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 165 TABLE 162 INDONESIA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 166 TABLE 163 INDONESIA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 166 TABLE 164 INDONESIA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 166 TABLE 165 INDONESIA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 167 TABLE 166 INDONESIA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 167 TABLE 167 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 168 TABLE 168 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 168 TABLE 169 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 169 TABLE 170 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 169 TABLE 171 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 169 TABLE 172 REST OF REST OF EUROPE WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 170 TABLE 173 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 170 TABLE 174 REST OF ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 171 TABLE 175 LATIN AMERICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 173 TABLE 176 LATIN AMERICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 174 TABLE 177 LATIN AMERICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 174 TABLE 178 LATIN AMERICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 174 TABLE 179 LATIN AMERICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 175 TABLE 180 LATIN AMERICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 175 TABLE 181 LATIN AMERICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 175 TABLE 182 LATIN AMERICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 176 TABLE 183 LATIN AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 176 TABLE 184 BRAZIL WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 177 TABLE 185 BRAZIL WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 177 TABLE 186 BRAZIL WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 178 TABLE 187 BRAZIL WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 178 TABLE 188 BRAZIL WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 178 TABLE 189 BRAZIL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 179 TABLE 190 BRAZIL WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 179 TABLE 191 BRAZIL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 179 TABLE 192 MEXICO WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 180 TABLE 193 MEXICO WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 180 TABLE 194 MEXICO WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 180 TABLE 195 MEXICO WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 181 TABLE 196 MEXICO WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 181 TABLE 197 MEXICO WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 181 TABLE 198 MEXICO WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 182 TABLE 199 MEXICO WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 182 TABLE 200 ARGENTINA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 183 TABLE 201 ARGENTINA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 183 TABLE 202 ARGENTINA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 183 TABLE 203 ARGENTINA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 184 TABLE 204 ARGENTINA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 184 TABLE 205 ARGENTINA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 184 TABLE 206 ARGENTINA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 185 TABLE 207 ARGENTINA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 185 TABLE 208 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 186 TABLE 209 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 186 TABLE 210 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 186 TABLE 211 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 187 TABLE 212 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 187 TABLE 213 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 187 TABLE 214 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 188 TABLE 215 REST OF LATIN AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 188 TABLE 216 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 190 TABLE 217 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 191 TABLE 218 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 191 TABLE 219 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 191 TABLE 220 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 192 TABLE 221 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 192 TABLE 222 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 192 TABLE 223 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 193 TABLE 224 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 193 TABLE 225 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 194 TABLE 226 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 194 TABLE 227 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 194 TABLE 228 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 195 TABLE 229 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 195 TABLE 230 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 195 TABLE 231 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 196 TABLE 232 GCC COUNTRIES WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 196 TABLE 233 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 197 TABLE 234 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 197 TABLE 235 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 197 TABLE 236 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 198 TABLE 237 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 198 TABLE 238 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 198 TABLE 239 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 199 TABLE 240 SOUTH AFRICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 199 TABLE 241 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY PRODUCT TYPE, 2019-2035 (USD MILLION) 200 TABLE 242 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY CONTRACEPTIVES, 2019-2035 (USD MILLION) 200 TABLE 243 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY FERTILITY AND OVULATION INDUCTION DRUGS, 2019-2035 (USD MILLION) 201 TABLE 244 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY VAGINAL AND UTERINE PRODUCTS, 2019-2035 (USD MILLION) 201 TABLE 245 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY BONE HEALTH AGENTS, 2019-2035 (USD MILLION) 201 TABLE 246 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2019-2035 (USD MILLION) 202 TABLE 247 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY AGE GROUP 2019-2035 (USD MILLION) 202 TABLE 248 REST OF MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL 2019-2035 (USD MILLION) 203 TABLE 249 KEY DEVELOPMENTS: GLOBAL WOMEN’S HEALTH MARKET 208 TABLE 250 BAYER AG: PRODUCTS OFFERED 212 TABLE 251 MERCK KGAA.: PRODUCT OFFERED 216 TABLE 252 PFIZER: PRODUCT OFFERED 219 TABLE 253 RECKITT BENCKISER: PRODUCT OFFERED 224 TABLE 254 CHURCH & DWIGHT CO., INC.: PRODUCT OFFERED 228 TABLE 255 ABBVIE INC.: PRODUCT OFFERED 233 TABLE 256 ORGANON & CO.: PRODUCT OFFERED 237 TABLE 257 MERCK & CO.: PRODUCT OFFERED 241 TABLE 258 FERRING PHARMACEUTICALS: PRODUCT OFFERED 244 TABLE 259 AMGEN: PRODUCT OFFERED 248 LIST OF FIGURES FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL WOMEN’S HEALTH MARKET, 2025 24 FIGURE 2 GLOBAL WOMEN’S HEALTH MARKET ANALYSIS, BY PRODUCT, 2025 (USD MILLION AND %) 25 FIGURE 3 GLOBAL WOMEN’S HEALTH MARKET ANALYSIS, BY THERAPEUTIC AREA, 2025 (USD MILLION AND %) 26 FIGURE 4 GLOBAL WOMEN’S HEALTH MARKET ANALYSIS, BY AGE GROUP, 2025 (USD MILLION AND %) 27 FIGURE 5 GLOBAL WOMEN’S HEALTH MARKET ANALYSIS, BY DISTRIBUTION CHANNEL, 2025 (USD MILLION AND %) 28 FIGURE 6 GLOBAL WOMEN’S HEALTH MARKET ANALYSIS, BY REGION, 2025 (USD MILLION AND %) 29 FIGURE 1 GLOBAL WOMEN'S HEALTH MARKET: STRUCTURE 32 FIGURE 2 GLOBAL WOMEN’S HEALTH MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2036) 49 FIGURE 3 GLOBAL WOMEN’S HEALTH MARKET DRIVER: IMPACT ANALYSIS 52 FIGURE 4 GLOBAL WOMEN’S HEALTH MARKET RESTRAINT: IMPACT ANALYSIS 54 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL WOMENS HEALTH MARKET 67 FIGURE 6 GLOBAL WOMEN’S HEALTH MARKET, PRODUCT SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 78 FIGURE 7 GLOBAL WOMEN’S HEALTH MARKET, BY PRODUCT, 2025 & 2035 (USD MILLION) 79 FIGURE 8 GLOBAL WOMEN’S HEALTH MARKET SHARE (%), BY PRODUCT, 2025 81 FIGURE 9 GLOBAL WOMEN’S HEALTH MARKET, THERAPEUTIC AREASEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 82 FIGURE 10 GLOBAL WOMEN’S HEALTH MARKET, BY THERAPEUTIC AREA, 2025 & 2035 (USD MILLION) 83 FIGURE 11 GLOBAL WOMEN’S HEALTH MARKET SHARE (%), BY THERAPEUTIC AREA, 2025 83 FIGURE 12 GLOBAL WOMEN’S HEALTH MARKET, AGE GROUP, SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 84 FIGURE 13 GLOBAL WOMEN’S HEALTH MARKET, BY AGE GROUP, 2025 & 2035 (USD MILLION) 85 FIGURE 14 GLOBAL WOMEN’S HEALTH MARKET SHARE (%), BY AGE GROUP, 2025 85 FIGURE 15 GLOBAL WOMEN’S HEALTH MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 86 FIGURE 16 GLOBAL WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2025 & 2035 (USD MILLION) 87 FIGURE 17 GLOBAL WOMEN’S HEALTH MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2025 88 FIGURE 18 GLOBAL WOMEN’S HEALTH MARKET, BY REGION, 2025 & 2035 (USD MILLION) 89 FIGURE 19 GLOBAL WOMEN’S HEALTH MARKET SHARE (%), BY REGION, 2025 90 FIGURE 20 NORTH AMERICA MARKET ANALYSIS: WOMEN’S HEALTH MARKET, 2019-2035 (USD MILLION) 91 FIGURE 21 NORTH AMERICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 92 FIGURE 22 NORTH AMERICA WOMEN’S HEALTH MARKET SHARE (%), BY COUNTRY, 2025 92 FIGURE 23 EUROPE MARKET ANALYSIS: WOMEN’S HEALTH MARKET, 2019-2035 (USD MILLION) 105 FIGURE 24 EUROPE WOMEN’S HEALTH MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 105 FIGURE 25 EUROPE WOMEN’S HEALTH MARKET SHARE (%), BY COUNTRY, 2025 106 FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: WOMEN’S HEALTH MARKET, 2019-2035 (USD MILLION) 139 FIGURE 27 ASIA-PACIFIC WOMEN’S HEALTH MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 140 FIGURE 28 ASIA-PACIFIC WOMEN’S HEALTH MARKET SHARE (%), BY COUNTRY, 2025 141 FIGURE 29 LATIN AMERICA MARKET ANALYSIS: WOMEN’S HEALTH MARKET, 2019-2035 (USD MILLION) 172 FIGURE 30 LATIN AMERICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 172 FIGURE 31 LATIN AMERICA WOMEN’S HEALTH MARKET SHARE (%), BY COUNTRY, 2025 173 FIGURE 32 MIDDLE EAST & AFRICA MARKET ANALYSIS: WOMEN’S HEALTH MARKET, 2019-2035 (USD MILLION) 189 FIGURE 33 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 189 FIGURE 34 MIDDLE EAST & AFRICA WOMEN’S HEALTH MARKET SHARE (%), BY COUNTRY, 2025 190 FIGURE 35 GLOBAL WOMEN’S HEALTHS MARKET: COMPETITIVE ANALYSIS, 2025 (%) 206 FIGURE 36 COMPETITOR DASHBOARD: GLOBAL WOMEN’S HEALTH MARKET 207 FIGURE 37 BAYER AG: SWOT ANALYSIS 212 FIGURE 38 MERCK KGAA: SWOT ANALYSIS 216 FIGURE 39 PFIZER: SWOT ANALYSIS 220 FIGURE 40 RECKITT BENCKISER: SWOT ANALYSIS 224 FIGURE 41 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS 229 FIGURE 42 ABBVIE INC.: SWOT ANALYSIS 233 FIGURE 43 ORGANON & CO.: SWOT ANALYSIS 237 FIGURE 44 MERCK & CO.: SWOT ANALYSIS 241 FIGURE 45 FERRING PHARMACEUTICALS: SWOT ANALYSIS 244 FIGURE 46 AMGEN.: SWOT ANALYSIS 248

提及公司

Bayer AGMerck KGaAPfizerReckitt BenckiserChurch & Dwight Co.Inc.AbbVie Inc.Organon & Co.Merck & Co.Ferring PharmaceuticalsAmgen Inc.

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們